drugset / Trial / NCT00002419
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
Phase 2
Completed
25 enrolled
Gilead Sciences
Dupont Applied Biosciences · collabGlaxo Wellcome · collab
Treatment
Summary
The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil plus abacavir (ABC) plus efavirenz (EFV) plus amprenavir (APV) to HIV-infected patients who have failed to respond to previous treatment with protease inhibitors (PIs).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | — | — |
| Subject | Adefovir dipivoxil | Small molecule | — | — |
| Subject | Amprenavir | Other / unclassified | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |